RJA
ONCS

Raymond James & Associates’s OncoSec Medical Incorporated ONCS Stock Holding History

Raymond James & Associates’s Portfolio ONCS Stock Details ONCS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-47
Closed -$6K – 3817
2019
Q1 		$6K Hold
47
– – ﹤0.01% 3585
2018
Q4 		$7K Buy
+47
New +$11.8K ﹤0.01% 3483

Other funds holding ONCS

6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CL
CSS LLC Chicago, Illinois $2.09B AUM 59.56% 1-Year Est. Return
WVP
Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Raymond James & Associates's ONCS Position: Q2 2019 in Review

Raymond James & Associates sold out of OncoSec Medical Incorporated (ONCS) in Q2 2019, closing a stake of 47 shares — an estimated $6K sold.

Raymond James & Associates first reported a position in ONCS in Q4 2018 and held it in 2 quarters. The position peaked at $7K in Q4 2018. 20 funds tracked by Wall St. Rank hold ONCS as of Q2 2019.

  • Raymond James & Associates reported no remaining OncoSec Medical Incorporated position as of Q2 2019 after selling out during the quarter.
  • Raymond James & Associates sold 47 OncoSec Medical Incorporated shares in Q2 2019, an estimated $6K.
  • Raymond James & Associates first reported a position in OncoSec Medical Incorporated in Q4 2018 and held it in 2 quarters.
  • Raymond James & Associates's OncoSec Medical Incorporated position peaked at $7K in Q4 2018.
  • 20 funds tracked by Wall St. Rank held OncoSec Medical Incorporated as of Q2 2019.

Based on Raymond James & Associates's 13F filing for Q2 2019, filed 6 Aug 2019.